drugset / Trial / NCT00003720

SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma

NCT00003720

Phase 1 Completed Pfizer
Treatment

Summary

RATIONALE: SU5416 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating patients who have AIDS-related Kaposi's sarcoma.

Timeline

Start
1998-07
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject semaxanib Small molecule Intravenous

Indications